Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX005M combinations in BRCA wild-type recurrent ovarian cancer
2020-005990-29Phase 2Terminated
- Sponsor
- Nordic Society of Gynaecological Oncology
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of sotigalimab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Nordic Society of Gynaecological Oncology. Primary endpoint: Overall Response Rate at 12 weeks. Started Oct 2021; status: terminated.
02
Drugs
sotigalimab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on 2020-005990-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005990-29.